P29 Outcomes by baseline pathogen and susceptibility in the ReSTORE Phase 3 trial of rezafungin once weekly compared with caspofungin once daily in patients with candidaemia and/or invasive candidiasis

BACKGROUND: Rezafungin is a next-generation, once-weekly echinocandin in development for treatment of candidaemia and invasive candidiasis (IC), and for prevention of invasive fungal diseases caused by Candida, Aspergillus, and Pneumocystis in allogeneic blood and marrow transplant recipients (Figur...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, G R, Soriano, A, Cornely, O A, Kullberg, B J, Kollef, M, Vazquez, J A, Das, A F, Locke, J B, Sandison, T, Pappas, P G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266148/
http://dx.doi.org/10.1093/jacamr/dlad066.033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266148/
http://dx.doi.org/10.1093/jacamr/dlad066.033

Ejemplares similares